PD‐L1 expression levels were shown to be variable in different metastatic lesions in the same patient and anti‐PD‐1 treatment response also seemed to be affected by tumor mutational load and preexisting intratumor CD8 +  T‐cells based on preclinical studies 56, 57, 58. The gene discussed is CD8A; the disease is neoplasm.